Daily Bio News Summary — 2026-10-09: A digital therapeutic first, a Teva reformulation win, and a drug-delivery patent ruling

Friday’s harvest produced nine new items across six sources — Fierce Pharma (2), Fierce Biotech (2), BioPharma Dive (2), Pharmaphorum (1), PR Newswire’s FDA approval feed (1) and MedCity News (1). The batch skews toward regulatory and platform news rather than dealmaking: a digital therapeutic clearance, a reformulated generic approved after years of effort, a drug-delivery patent ruling, and a vaccine-manufacturing finding.

It is a deliberately short list because most of this morning’s front pages were still carrying Thursday’s stories, which were already published in the previous harvest. What follows is only what was genuinely new.

Digital therapeutics: Click clears a first in schizophrenia

Pharmaphorum reported that Click Therapeutics has claimed FDA clearance for a first-in-class digital therapeutic aimed at schizophrenia (Pharmaphorum, 2026-10-09). The company develops prescription-software treatments for neuropsychiatric and neurological conditions, and this is the first product in its portfolio framed as first-in-class for schizophrenia.

The regulatory framing here matters. The headline describes a digital therapeutic clearing an FDA gate, which places software inside a treatment paradigm built around pharmacology. This item is treated here as a pipeline event for Click rather than as a characterization of the cleared product’s clinical profile.

Teva finally lands a reformulated olanzapine

Fierce Pharma reports Teva has secured FDA approval for a reformulated, long-acting olanzapine product, described as a “long-sought” nod (Fierce Pharma, 2026-10-09). Reformulations of off-patent molecules are one of the few remaining levers for generic manufacturers facing price erosion on the base molecule, and this one has been the subject of sustained regulatory back-and-forth.

Drug delivery: Halozyme prevails against Merck in a patent fight

BioPharma Dive reports that Halozyme prevailed in a patent dispute with Merck, in a story bundled with news that Enliven Therapeutics is preparing an anticipated leukemia trial (BioPharma Dive, 2026-10-09). Halozyme’s franchise rests on its ENHANZE recombinant human hyaluronidase platform, which enables subcutaneous administration of partner biologics — so patent outcomes around subcutaneous formulations are not a side issue for the company, they are the core asset.

The item is a reminder that subcutaneous delivery has become a strategic chokepoint for the industry’s largest antibody franchises, and that platform ownership is what Halozyme monetizes.

AI: GSK adopts Chai’s models after wet-lab validation

Fierce Biotech reported that GSK will adopt Chai’s AI models after a wet-lab validation exercise (Fierce Biotech, 2026-10-09). The framing matters: the headline emphasizes validation rather than announcement, which is the pattern to watch as large pharma buyers move from piloting AI-generated designs to requiring prospective experimental confirmation before committing.

Vaccines: a manufacturing finding at CSL Seqirus

Fierce Pharma reports CSL Seqirus was faulted for “multiple and prolonged deficiencies” (Fierce Pharma, 2026-10-08). The item does not specify the inspecting authority or the site, but Seqirus is one of the largest global influenza vaccine suppliers, and manufacturing findings at that scale carry supply implications going into the Northern Hemisphere season. The company is currently being separated into a standalone business as part of CSL’s restructuring.

Also in the batch

Lupin received US FDA approval for phytonadione injectable emulsion USP (PR Newswire FDA, 2026-10-08) — a generic vitamin K injectable, the kind of routine approval that rarely makes trade headlines but matters for hospital formulary supply.

Vir Biotechnology is repositioning its late-stage leadership, with the company looking to a new executive to lead that push (Fierce Biotech, 2026-10-09), alongside broader industry executive movement reported the same day.

A Takeda spinout is building its case for a Parkinson’s drug (BioPharma Dive, 2026-10-09) — the source frames this as a spinout advancing a central-nervous-system asset, a category where clinical validation has historically been unforgiving.

Arboretum, a startup bringing a precision-medicine approach to common diseases, launched this week (MedCity News, 2026-10-01). Early-stage company formation is a leading indicator, but there is no clinical data behind this item yet.

What this batch is NOT telling us

• No M&A, no IPO pricings, no Phase 3 readouts. Thursday’s harvest carried the week’s big transactions and trial data; this morning’s genuinely-new set contains none. That is a function of publishing cadence, not of the industry going quiet.
• A large share of today’s candidate articles was gated. The Endpoints News items surfaced on this morning’s homepage — including coverage of a new PDUFA deal, an FDA clinical-trial modernization office, and several pipeline decisions — resolved to soft-paywalled pages and were excluded. Their absence from this summary does not mean those events were unimportant; it means the free version was not available at harvest time.
• Absence of a topic is not evidence. Several items that appear to be “missing” — argenx’s Sjögren’s setback, Viatris’s Pacira acquisition, Caribou’s wind-down, the optogenetics Nobel — were published here earlier in the week and were deduplicated out of today’s batch.

Reading order

If you have five minutes:

1. Click’s schizophrenia digital therapeutic — the most structurally interesting approval in the batch.
2. Teva’s reformulated olanzapine — a reminder that reformulation, not invention, is where much generic value now sits.
3. Halozyme v. Merck — subcutaneous delivery is a strategic chokepoint for the industry’s biggest antibodies.
4. GSK’s Chai validation — a concrete data point on how pharma is buying AI.
5. CSL Seqirus manufacturing finding — supply relevance for the flu season.

How to read the underlying articles

Every item above is a frontmatter-only record in src/content/news/. The sourceUrl field in each markdown file points at the original article; sourceName identifies the publisher, and pubDate gives the publication date used for the 30-day freshness filter. Items skipped for staleness, duplication, paywall or topic reasons are intentionally not listed here.

Today’s items

1. Click claims FDA okay for first-in-class schizophrenia DTx — Pharmaphorum, 2026-10-09
2. Teva bags long-sought reformulated olanzapine schizophrenia nod — Fierce Pharma, 2026-10-09
3. GSK drinks in Chai’s AI models after wet-lab validation — Fierce Biotech, 2026-10-09
4. Vir looks to Liu to lead late-stage push — Fierce Biotech, 2026-10-09
5. A Takeda spinout builds case for its Parkinson’s drug — BioPharma Dive, 2026-10-09
6. Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial — BioPharma Dive, 2026-10-09
7. Lupin receives U.S. FDA approval for phytonadione injectable emulsion, USP — PR Newswire FDA, 2026-10-08
8. CSL Seqirus blasted for “multiple and prolonged deficiencies” — Fierce Pharma, 2026-10-08
9. Startup Arboretum sprouts, bringing a precision medicine approach to common diseases — MedCity News, 2026-10-01